Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.

about

Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.

Item

http://www.wikidata.org/entity/Q40081751

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Reolysin and Histone Deacetyla ...... Neck Squamous Cell Carcinoma.

@en

type

Item

label

Reolysin and Histone Deacetyla ...... Neck Squamous Cell Carcinoma.

@en

prefLabel

Reolysin and Histone Deacetyla ...... Neck Squamous Cell Carcinoma.

@en

P1476

Reolysin and Histone Deacetyla ...... Neck Squamous Cell Carcinoma.

@en

P2093

Alena C Jaime-Ramirez

http://www.w3.org/2001/XMLSchema#string

Balveen Kaur

http://www.w3.org/2001/XMLSchema#string

Bhavna Kumar

http://www.w3.org/2001/XMLSchema#string

Craig Hofmeister

http://www.w3.org/2001/XMLSchema#string

Enrico Caserta

http://www.w3.org/2001/XMLSchema#string

Flavia Pichiorri

http://www.w3.org/2001/XMLSchema#string

Ji Young Yoo

http://www.w3.org/2001/XMLSchema#string

Jianying Zhang

http://www.w3.org/2001/XMLSchema#string

John H Lee

http://www.w3.org/2001/XMLSchema#string

Jun-Ge Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade

Epigenetic treatment of solid tumours: a review of clinical trials

New and emerging HDAC inhibitors for cancer treatment

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma

Immunogenic and tolerogenic cell death.

Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.

Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1.

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.

P304

87-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OMTO.2017.05.002

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28812060

http://www.w3.org/2001/XMLSchema#string

P932

5440762

http://www.w3.org/2001/XMLSchema#string